Crovalimab + Placebo + VKA
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Antiphospholipid Syndrome
Conditions
Antiphospholipid Syndrome
Trial Timeline
Mar 16, 2026 → Dec 2, 2030
NCT ID
NCT07172022About Crovalimab + Placebo + VKA
Crovalimab + Placebo + VKA is a phase 2 stage product being developed by Roche for Antiphospholipid Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT07172022. Target conditions include Antiphospholipid Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07172022 | Phase 2 | Withdrawn |
Competing Products
4 competing products in Antiphospholipid Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RAY121 | Chugai Pharmaceutical | Phase 1 | 33 |
| RAY121 | Chugai Pharmaceutical | Phase 1 | 33 |
| Apixaban + Warfarin | Bristol Myers Squibb | Approved | 84 |
| Rivaroxaban | Bayer | Approved | 82 |